Vischer Advises Oculis Holding on USD 110 Million Equity Financing

"Vischer advised Oculis Holding on the pricing of an offering of 5,432,098 ordinary shares at $20.25 per unit, raising gross proceeds of USD 110 million. Oculis will use net proceeds to advance a novel neuroprotective clinical candidate and for working capital and general corporate purposes."

Vischer advised Oculis Holding, the globally active biopharmaceutical company, in connection with the recent financing transaction. Oculis Holding announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per unit, producing total gross proceeds of USD 110 million. The company intends to use the net proceeds from the financing to advance the development of a novel neuroprotective clinical candidate and for working capital and general corporate purposes. Vischer represented Oculis Holding with a team composed by: Matthias Staehelin, Vincent Reardon, Balthasar Müller and Elena Weller (corporate/M&A), and Nadia Tarolli Schmidt and Patrik Fisch (tax).

Vischer Advises Oculis Holding on USD 110 Million Equity Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads